PO.ET05.01 · 实验与分子治疗

全氟和多氟烷基物质(PFAS)促进遗传背景不同的肾癌细胞系的增殖和迁移

Per and polyfluoroalkyl substances (PFAS) promote proliferation and migration in genetically distinct kidney cancer cell lines

海报缩略图:全氟和多氟烷基物质(PFAS)促进遗传背景不同的肾癌细胞系的增殖和迁移
编号 5691 展板 7 时间 4/21 02:00–05:00 区域 Section 12 主讲 RAKESH ARYA, PhD
分会场 Mechanisms of Anticancer Drug Action
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Rakesh Kumar Arya1, Mia Sand2, Sahab Ram Dewala1, Can Aydogdu3, Gabriela M. Diaz3, Christopher Weight3, Riccardo Autorino3, Abhishek Chakraborty4, Jacob M. Knorr3, Joseph M. K. Irudayaraj2, Laura Bukavina3

1Center for Immunotherapy and Precision Immuno-oncology, Cleveland Clinic Lerner Research Institute, Cleveland, OH,2Department of Bioengineering,, University of Illinois Urbana-Champaign, Champaign, IL,3Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH,4Department of Cancer Biology, Cleveland Clinic Research, Cleveland, OH

摘要 Abstract

中文摘要
引言与目的:全氟和多氟烷基物质(PFAS),如GenX、PFOA和PFOS,是持久性环境污染物,越来越多地与肾脏致癌相关。它们对肾癌进展的直接影响仍不清楚。本研究调查了PFAS暴露是否会增强两种遗传背景不同的肾癌模型——人RCC-ER(VHL突变型)和小鼠Renca(VHL野生型)——的增殖和迁移。 方法:以生理相关浓度(0.5-40 nM)用GenX、PFOA或PFOS处理RCC-ER和Renca细胞。使用IncuCyte S3系统监测72小时内的增殖。在ImageLock板中评估迁移,于24小时后制造划痕,并每1.5小时成像一次,持续72小时。使用IncuCyte软件通过划痕闭合百分比(WC)和相对划痕密度(RWD)对划痕闭合进行定量。所有实验均一式三份进行,以评估剂量依赖性和统计学显著性。 结果:PFAS暴露显著增强了肾癌细胞的增殖和迁移,并存在化合物特异性和细胞系特异性差异。Renca细胞对0.5-20 nM的GenX和PFOS表现出强烈的增殖反应,分别在5 nM时达到峰值,而PFOA在这些剂量下显示出细胞毒性效应。相比之下,RCC-ER细胞对PFOA(在40 nM时最大)和PFOS(在5 nM时最大)反应表现出增殖增加,而GenX在低剂量下对增殖影响极小。所有三种PFAS均显著加速了两种细胞系的划痕闭合和相对划痕密度,表明迁移潜能增强。总体而言,这些数据揭示PFAS化合物在人和小鼠肾癌模型中均增强了促癌行为。 结论:PFAS化合物通过不同但趋同的代谢机制在小鼠和人肾癌模型中促进增殖和迁移表型。在VHL野生型和VHL突变型系统中的保守效应凸显PFAS作为肾肿瘤进展的潜在环境加速因子,值得进一步开展机制和转化研究。
查看英文原文 English abstract
Introduction and Objectives: Per- and polyfluoroalkyl substances (PFAS) such as GenX, PFOA, and PFOS are persistent environmental pollutants increasingly associated with renal carcinogenesis. Their direct effects on kidney cancer progression remain unclear. This study investigated whether PFAS exposure enhances proliferation and migration in two genetically distinct kidney cancer models-human RCC-ER (VHL-mutant) and murine Renca (VHL-wild type). Methods: RCC-ER and Renca cells were treated with GenX, PFOA, or PFOS at physiologically relevant concentrations (0.5-40 nM). Proliferation was monitored over 72 h using the IncuCyte S3 system. Migration was assessed in ImageLock plates, where wounds were created after 24 h and imaged every 1.5 h for 72 h. Wound closure was quantified by percentage wound closure (WC) and relative wound density (RWD) using IncuCyte software. All experiments were performed in triplicate to assess dose dependency and statistical significance. Results: PFAS exposure significantly enhanced both proliferation and migration in kidney cancer cells, with compound- and cell line-specific variations. RenCa cells exhibited strong proliferative responses to GenX and PFOS from 0.5-20 nM, peaking at 5 nM respectively, while PFOA showed cytotoxic effects at these doses. In contrast, RCC-ER cells demonstrated increased proliferation in response to PFOA (max at 40 nM) and PFOS (max at 5 nM), whereas GenX had minimal effect on proliferation at low doses. All three PFAS markedly accelerated wound closure and relative wound density in both cell lines, indicating enhanced migratory potential. Collectively, these data reveal that PFAS compounds augment pro-oncogenic behaviors across human and murine kidney cancer models. Conclusion: PFAS compounds promote proliferative and migratory phenotypes in both murine and human kidney cancer models through distinct but convergent metabolic mechanisms. The conserved effects across VHL-wild-type and VHL-mutant systems underscore PFAS as a potential environmental accelerator of renal tumor progression and justify further mechanistic and translational studies.
利益披露 Disclosure
R. K. Arya, None.. M. Sand, None.. S. Dewala, None.. C. Aydogdu, None.. G. M. Diaz, None.. C. Weight, None.. R. Autorino, None.. A. Chakraborty, None.. J. M. Knorr, None.. J. M. K. Irudayaraj, None.. L. Bukavina, None.

← 返回 AACR 2026 检索